硒蛋白P1(SEPP1)單克隆抗體
Monoclonal Antibody to Selenoprotein P1, Plasma (SEPP1)
SEPP; SeP; SEP-P1; SELP
- 編號(hào)MAB809Hu24
- 物種Homo sapiens (Human，人)相同的名稱(chēng)，不同的物種。
- 來(lái)源單抗制備
- 宿主小鼠
- 效價(jià)(克隆號(hào))H4
- Ig亞型 IgG1 Kappa
- 純化方式蛋白A + 蛋白G親和純化
- 標(biāo)記物無(wú)標(biāo)記物
- 免疫原RPB809Hu01-硒蛋白P1(SEPP1)重組蛋白
- 緩沖液成份0.01M 磷酸鹽緩沖液（pH7.4，containing 0.05% Proclin-300，50% glycerol）
- 性狀液體
- 濃度1mg/mL
- 且適物種-
- 應(yīng)用IHC
如果抗體需用于流式細(xì)胞術(shù)，請(qǐng)參見(jiàn)流式抗體。 - 下載英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格20μl100μl200μl1ml10ml
- 價(jià)格¥ 670¥ 1562¥ 2232¥ 5580¥ 22320
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷(xiāo)商聯(lián)系!
產(chǎn)品包裝(模擬)
產(chǎn)品包裝(模擬)
DAB staining on IHC-P; Sample: Human Kidney Tissue; Primary Ab: 20μg/ml Mouse Anti-Human SEPP1 Antibody Second Ab: 2μg/mL?HRP-Linked Caprine Anti-Mouse IgG Polyclonal Antibody (Catalog: SAA544Mu19)
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
特異性
該抗體是針對(duì)SEPP1的小鼠單克隆抗體。在免疫組織化學(xué)染色和免疫印跡實(shí)驗(yàn)中能識(shí)別SEPP1。
用法
Western blotting: 0.5-2μg/mL;
Immunohistochemistry: 5-20μg/mL;
Immunocytochemistry: 5-20μg/mL;
Optimal working dilutions must be determined by end user.
儲(chǔ)存
經(jīng)常使用則4°C保存。-20°C保存不超過(guò)兩年。避免反復(fù)凍融。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
抗體標(biāo)記定制服務(wù)
Protein-A/G純化柱
細(xì)胞和組織染色液
抗體陽(yáng)性對(duì)照品
組織/切片定制服務(wù)
磷酸化抗體定制服務(wù)
免疫印跡(WB)實(shí)驗(yàn)服務(wù)
免疫組織化學(xué)(IHC)實(shí)驗(yàn)服務(wù)
免疫細(xì)胞化學(xué)(ICC)實(shí)驗(yàn)服務(wù)
流式細(xì)胞術(shù)(FCM)實(shí)驗(yàn)服務(wù)
免疫沉淀(IP)實(shí)驗(yàn)服務(wù)
免疫熒光(IF)實(shí)驗(yàn)服務(wù)
緩沖液
DAB顯色試劑盒
SABC試劑盒
長(zhǎng)臂生物素標(biāo)記試劑盒
實(shí)時(shí)熒光定量PCR實(shí)驗(yàn)服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Homo sapiens (Human，人) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| RPB809Hu01 | 硒蛋白P1(SEPP1)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAB809Hu01 | 硒蛋白P1(SEPP1)多克隆抗體 | WB; IHC; ICC; IP. |
| LAB809Hu81 | 硒蛋白P1(SEPP1)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| LAB809Hu71 | 硒蛋白P1(SEPP1)多克隆抗體(生物素標(biāo)記) | WB; IHC; ICC. |
| MAB809Hu25 | 硒蛋白P1(SEPP1)單克隆抗體 | WB; IHC; ICC; IP. |
| MAB809Hu22 | 硒蛋白P1(SEPP1)單克隆抗體 | WB |
| MAB809Hu23 | 硒蛋白P1(SEPP1)單克隆抗體 | IHC |
| MAB809Hu24 | 硒蛋白P1(SEPP1)單克隆抗體 | IHC |
| MAB809Hu21 | 硒蛋白P1(SEPP1)單克隆抗體 | WB; ICC/IF |
| SEB809Hu | 硒蛋白P1(SEPP1)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| LMB809Hu | 硒蛋白P1(SEPP1)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| The Journal of Clinical Endocrinology & Metabolism | Serum Selenoprotein P Levels in Patients with Type 2 Diabetes and Prediabetes: Implications for Insulin Resistance, Inflammation, and Atherosclerosis[PubMed: 21677040] |
| Diabetes & metabolism journal | Increased Selenoprotein P Levels in Subjects with Visceral Obesity and Nonalcoholic Fatty Liver Disease[PubMed: 23439771] |
| Journal of Pediatric Biochemistry | Trace elements, heavy metals and vitamins in Egyptian school children with iron deficiency anemia[Metapress:Source] |
| Journal of Trace Elements in Medicine and Biology | Selenium and its relationship with selenoprotein P and glutathione peroxidase in children and adolescents with Hashimoto's thyroiditis and hypothyroidism[PubMed: 26854239] |
| OBES RES CLIN PRACT/OBESITY RESEARCH & CLINICAL PRACTICE | Selenoprotein?P?is?elevated?in?individuals?with?obesity, but is not?independently?associated?withinsulin?resistance.[pubmed:27524654] |
| Annals of Nutrition and Metabolism | Acute?Overfeeding?Does Not Alter Liver or?Adipose?Tissue-Derived?Cytokines?in?HealthyHumans.[pubmed:27832637] |
| European?Journal?of?Nutrition | DNA?damage?and?oxidative?stress?response?to?selenium?yeast?in the?non-smoking?individuals: ashort-term?supplementation?trial?with?respect?to?GPX1?and SEPP1 polymorphism.[pubmed:26658762] |
| South. Clin. Ist. Euras. | Evaluation of the Relationship Between Insulin Resistance and Selenoprotein P in Patients with Polycystic Ovary Syndrome[DOI: 10.14744/scie.2017.87597] |
| Arch Endocrinol Metab | Serum selenium and selenoprotein-P levels in autoimmune thyroid dieases patients in a select center a transversal study[DOI: 10.1590/2359-3997000000309] |
| British Journal of Nutrition | Selenium, selenoproteins and selenometabolites in mothers and babies at the time of birth[pubmed:28534447] |
| Journal of?Trace?Elements?in Medicine and Biology | Biomarkers of selenium status and antioxidant effect in workers occupationally exposed to mercury[Pubmed:29895371] |
| Biological &?Pharmceutical Bulletin | Comparison of Human Selenoprotein P Determinants in Serum between Our Original Methods and Commercially Available Kits[Pubmed:29709922] |
| Diabetologia | Non-alcoholic fatty liver disease in the first trimester and subsequent development of gestational diabetes mellitus[Pubmed: 30470912] |
| Biological Trace Element Research | Selenium Levels in Community Dwellers with Type 2 Diabetes Mellitus[Pubmed: 30725267] |
| Advances in?Medical?Sciences | Can hepatokines be regarded as novel non-invasive serum biomarkers of intrahepatic lipid content in obese children?[Pubmed: 30921653] |
| Acute swimming exercise, but not exposure to moderate hypoxic conditions reduces circulating selenoprotein P levels in short-term, high-fat diet-fed rats[Pubmed: 31236416] | |
| Hormones | Selenium and selenoprotein P in nonalcoholic fatty liver disease[Pubmed: 31493247] |
| Bull Environ Contam Toxicol | Soil Selenium Concentration and Residents Daily Dietary Intake in a Selenosis Area: A Preliminary Study in Yutangba Village, Enshi City, China[Pubmed: 32909074] |
| INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | Higher Serum Selenoprotein P Level as a Novel Inductor of Metabolic Complications in Psoriasis[Pubmed: 32605214] |
| Circulating hepassocin level in patients with stable angina is associated with fatty liver and renal function[] | |
| Nat Immunol | Selenium–GPX4 axis protects follicular helper T cells from ferroptosis[34413521] |
| Reviews in Cardiovascular Medicine | Selenoprotein P-1 (SEPP1) as An Early Biomarker of Acute Kidney Injury in Patients Undergoing Cardiopulmonary Bypass[] |